Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12555062 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Le XF, et al. (2003) Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22, 484-97 12555062
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T412-p - p70S6K (human)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphoamino acid analysis, western blotting
 Disease tissue studied:  breast cancer, ovarian cancer
 Relevant cell lines - cell types - tissues:  BT-474 (breast cell), SKBr3 (breast cell), SKOV-3 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol no change compared to control

S434-p - p70S6K (human)
Orthologous residues
p70S6K (human): S434‑p, p70S6K iso2 (human): S411‑p, p70S6K (mouse): S434‑p, p70S6K (rat): S434‑p, p70S6K iso2 (rat): S411‑p, p70S6K (fruit fly): S418‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphoamino acid analysis, western blotting
 Disease tissue studied:  breast cancer, ovarian cancer
 Relevant cell lines - cell types - tissues:  BT-474 (breast cell), SKBr3 (breast cell), SKOV-3 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol no change compared to control

T444-p - p70S6K (human)
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphoamino acid analysis, western blotting
 Disease tissue studied:  breast cancer, ovarian cancer
 Relevant cell lines - cell types - tissues:  BT-474 (breast cell), SKBr3 (breast cell), SKOV-3 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
actinomycin D taxol inhibit treatment-induced increase
cycloheximide taxol inhibit treatment-induced increase
PD98059 taxol inhibit treatment-induced increase
PD184352 taxol inhibit treatment-induced increase
SB203580 taxol inhibit treatment-induced increase
SB202190 taxol inhibit treatment-induced increase
SP600125 taxol inhibit treatment-induced increase
GF109203X taxol inhibit treatment-induced increase
Ro31-8425 taxol inhibit treatment-induced increase
BAPTA-AM taxol inhibit treatment-induced increase
U73122 taxol inhibit treatment-induced increase
wortmannin taxol inhibit treatment-induced increase
LY294002 taxol inhibit treatment-induced increase
rapamycin taxol inhibit treatment-induced increase

S447-p - p70S6K (human)
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphoamino acid analysis, western blotting
 Disease tissue studied:  breast cancer, ovarian cancer
 Relevant cell lines - cell types - tissues:  BT-474 (breast cell), SKBr3 (breast cell), SKOV-3 (ovarian)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
actinomycin D taxol inhibit treatment-induced increase
cycloheximide taxol inhibit treatment-induced increase
PD98059 taxol inhibit treatment-induced increase
PD184352 taxol inhibit treatment-induced increase
SB203580 taxol inhibit treatment-induced increase
SB202190 taxol inhibit treatment-induced increase
SP600125 taxol inhibit treatment-induced increase
GF109203X taxol inhibit treatment-induced increase
Ro31-8425 taxol inhibit treatment-induced increase
BAPTA-AM taxol inhibit treatment-induced increase
U73122 taxol inhibit treatment-induced increase
wortmannin taxol inhibit treatment-induced increase
LY294002 taxol inhibit treatment-induced increase
rapamycin taxol inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.